Skip to main content

HubXchange

HubXChange logo

Antibody Therapeutics Xchange - San Diego - 2025

Page Banner 1

  1. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Revolutionizing Cancer Therapeutics: Next-Generation Antibody-Drug Conjugates with Precision Targeting and Optimized Payloads
  2. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Overcoming linker stability issues in antibody-drug conjugates (Topic TBC)
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Spotlight Presentation: Accelerating Therapeutic Antibody Development: Merging AI with High-Throughput Biology
    Spotlight Presentation: Accelerating Therapeutic Antibody Development: Merging AI with High-Throughput Biology
    Alon Wellner
    Alon Wellner, VP of Biology - Aureka Bio
  4. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Key considerations in designing ADCs to minimize resistance development
    What are the key considerations for target selection to enhance ADC efficacy? What should be the pay ...
    Bishnu Nayak
    Bishnu Nayak, Senior Director and Site Head - NeologicsBio
  5. Bi/Multispecifics
    • Bi/Multispecifics
    Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Drinks-Canape Reception
  7. Lead Identification & Optimization
    • Lead Identification & Optimization
    Next generation antibodies addressing the road blocks for first generations [Topic TBC]
    Christopher Roth
    Christopher Roth, Vice President of Research - Abilita Therapeutics, Inc.
  8. Formats & Scaffolds
    • Formats & Scaffolds
    AI-Powered Design and Engineering of Biologics: Unlocking Novel Formats and Scaffolds for Challenging Targets
  9. Lead Identification & Optimization
    • Lead Identification & Optimization
    Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Afternoon Refreshments
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Spotlight Presentation
    Spotlight Presentation
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Networking Lunch
  15. Bi/Multispecifics
    • Bi/Multispecifics
    Addressing the toxicity profile of bispecific antibodies: managing cytokine release and off-target effects (Topic TBC)
  16. Formats & Scaffolds
    • Formats & Scaffolds
    Which are the best approaches to overcome lower affinity for target specificity and efficacy
    Which are the best approaches to overcome lower affinity for target specificity and efficacy
    Christilyn Graff
    Christilyn Graff, Senior Vice President, Head of Research - Mosaic Biosciences
  17. Lead Identification & Optimization
    • Lead Identification & Optimization
    Optimizing antibody glycosylation profiles for enhanced effector functions in lead development (Topic TBC)
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Morning Refreshments
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
  21. Bi/Multispecifics
    • Bi/Multispecifics
    Developing therapies to target multiple immune pathways
    Max Cherf
    Max Cherf, Director, Mammalian Display - Tentarix Biotherapeutics
  22. Formats & Scaffolds
    • Formats & Scaffolds
    Function over Form: Addressing immunogenicity risk and other barriers to clinical development of non-conventional antibody therapeutics
    Is broad-based use of conventional IgG somewhat limited by its fundamental biophysical properties? A ...
    Jacob Gano
    Jacob Gano, Head of Antibody Engineering - Protillion Biosciences
  23. Lead Identification & Optimization
    • Lead Identification & Optimization
    Novel strategies for optimizing antibody stability and half-life
    What are the key issues faced in the in vitro degradation of antibodies, and which (bio)chemical pat ...
    Alex Sevy
    Alex Sevy, Director of Antibody Therapeutics - Aegis Life
  24. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Selecting disease-specific antigens to minimise ADC toxicity to healthy cells
    Anindya Bagchi
    Anindya Bagchi, Co-Founder - Styx Biotechnologies Incorporated
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Opening Address & Keynote Presentation
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Registration
Search